{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:39:42Z","timestamp":1769636382326,"version":"3.49.0"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,7,1]]},"abstract":"<jats:sec><jats:title>Objectives.<\/jats:title><jats:p>Severe neonatal jaundice is a common clinical manifestation of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and the most difficult to manage; kernicterus is not an uncommon outcome. We assessed in healthy, direct Coombs test-negative Greek newborns of \u226538 weeks' gestational age 1) the current burden of G-6-PD deficiency-associated severe jaundice, and 2) the efficacy of preventive use of Sn-mesoporphyrin (SnMP), a potent inhibitor of heme oxygenase activity and thus of bilirubin production, in ameliorating jaundice in G-6-PD-deficient neonates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The studies were conducted at Metera Maternity Hospital in Athens, Greece. Enrolled newborns had the plasma bilirubin concentration (PBC) determined in cord blood and daily thereafter until a declining level was obtained and the case was closed. Intervention with phototherapy was dictated at exact, age-specific PBC levels. In our initial study, we enrolled consecutive mature healthy G-6-PD-deficient newborns as well as a threefold excess of G-6-PD-normal neonates born at approximately the same time (control group). For the SnMP trial, G-6-PD-deficient neonates were administered SnMP as a single intramuscular dose of 6 \u03bcmol\/kg birth weight within 24 \u00b1 12 hours of age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>SnMP was administered at 26.7 \u00b1 6.1 hours of age to 172 G-6-PD-deficient newborns (group A); 168 G-6-PD-normal (group B) and 58 G-6-PD-deficient (group C) newborns who were enrolled earlier provided the comparison groups. Except for the expected excess of males in the G-6-PD-deficient groups (A and C), there were no differences in the demographic characteristics among the 3 groups. The incremental changes in PBC from cord blood to 24 hours of age also were similar (group A: 4.13 \u00b1 1.32 mg\/dL; group B: 4.05 \u00b1 1.34 mg\/dL; group C: 4.39 \u00b1 1.07 mg\/dL), but there were significant differences in the next period, 24 to 48 hours of age (group A: 0.63 \u00b1 1.44 mg\/dL; group B: 1.69 \u00b1 1.5 mg\/dL; group C: 2.45 \u00b1 1.72 mg\/dL). Peak PBC was significantly different (group A: 7.81 \u00b1 3.04 mg\/dL; group B: 8.68 \u00b1 3.1 mg\/dL; group C: 11.24 \u00b1 3.76 mg\/dL) as was the age at which peak PBC was recorded (group A: 56 \u00b1 29 hours of age; group B: 69 \u00b1 26 hours of age; group C: 83 \u00b1 29 hours of age). These differences in favor of group A were observed despite the fact that phototherapy was used in 15% of the newborns in group B and 31% of those in group C, whereas none of those treated with SnMP required phototherapy. Finally, in one female, who was heterozygous for G-6-PD deficiency, in group C phototherapy failed and 2 exchange transfusions were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>In comparison with normal neonates, G-6-PD-deficient neonates experienced a twofold increase in the prevalence of significant hyperbilirubinemia requiring phototherapy. A single dose of SnMP administered in the 1st day of life to the G-6-PD-deficient newborns shifted the peak PBC distribution to the left (lower values) even in relation to normal neonates and entirely eliminated the need for phototherapy. Interdiction of bilirubin production by use of a heme oxygenase inhibitor such as SnMP represents a simple and highly effective means for the preventive management of jaundice in G-6-PD-deficient newborns.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.108.1.25","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"25-30","source":"Crossref","is-referenced-by-count":65,"title":["A Single Dose of Sn-Mesoporphyrin Prevents Development of Severe Hyperbilirubinemia in Glucose-6-Phosphate Dehydrogenase-Deficient Newborns"],"prefix":"10.1542","volume":"108","author":[{"given":"Attallah","family":"Kappas","sequence":"first","affiliation":[{"name":"From Rockefeller University Hospital, New York, New York; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George S.","family":"Drummond","sequence":"additional","affiliation":[{"name":"From Rockefeller University Hospital, New York, New York; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timos","family":"Valaes","sequence":"additional","affiliation":[{"name":"Metera Maternity Hospital, Athens, Greece, and New England Medical Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2001,7,1]]},"reference":[{"key":"2021121011035098500_B1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(60)91028-X","article-title":"Erythrocyte enzyme deficiency in unexplained kernicterus.","volume":"1","author":"Smith","year":"1960","journal-title":"Lancet"},{"key":"2021121011035098500_B2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0140-6736(60)92688-X","article-title":"Erythrocyte enzyme deficiency in unexplained kernicterus.","volume":"2","author":"Doxiadis","year":"1960","journal-title":"Lancet"},{"key":"2021121011035098500_B3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0140-6736(60)91904-8","article-title":"Enzyme deficiency in hemolytic disease of the newborn.","volume":"2","author":"Weatherall","year":"1960","journal-title":"Lancet"},{"key":"2021121011035098500_B4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(60)92177-2","article-title":"Erythrocyte enzyme deficiency in unexplained kernicterus.","volume":"2","author":"Panizon","year":"1960","journal-title":"Lancet"},{"key":"2021121011035098500_B5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0140-6736(61)91476-3","article-title":"Glucose-6-phosphate dehydrogenase deficiency: a new aetiological factor of severe neonatal jaundice.","volume":"1","author":"Doxiadis","year":"1961","journal-title":"Lancet"},{"key":"2021121011035098500_B6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1651-2227.1994.tb13216.x","article-title":"Severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency: pathogenesis and global epidemiology.","volume":"83","author":"Valaes","year":"1994","journal-title":"Acta Paediatr"},{"key":"2021121011035098500_B7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1542\/peds.96.4.734","article-title":"Hidden risks: early discharge and bilirubin toxicity due to glucose-6-phosphate dehydrogenase deficiency.","volume":"96","author":"MacDonald","year":"1995","journal-title":"Pediatrics"},{"key":"2021121011035098500_B8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0095-5108(18)30098-8","article-title":"Severe neonatal hyperbilirubinemia: a potential complication of glucose-6-phosphate dehydrogenase deficiency.","volume":"25","author":"Kaplan","year":"1998","journal-title":"Clin Perinatol"},{"key":"2021121011035098500_B9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/adc.39.208.545","article-title":"The clinical picture of glucose-6-phosphate dehydrogenase deficiency in early infancy.","volume":"39","author":"Doxiadis","year":"1964","journal-title":"Arch Dis Child"},{"key":"2021121011035098500_B10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1651-2227.1996.tb14013.x","article-title":"The impact of phototherapy in the management of neonatal hyperbilirubinemia: comparison of historical cohorts.","volume":"85","author":"Valaes","year":"1996","journal-title":"Acta Paediatr"},{"key":"2021121011035098500_B11","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1073\/pnas.78.10.6466","article-title":"Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation.","volume":"78","author":"Drummond","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021121011035098500_B12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0003-9861(87)90294-3","article-title":"Reduction of the C2 and C4 vinyl groups of Sn-protoporphyrin to form Sn-mesoporphyrin markedly enhances the ability of the metalloporphyrin to inhibit in vivo heme catabolism.","volume":"255","author":"Drummond","year":"1987","journal-title":"Arch Biochem Biophys"},{"key":"2021121011035098500_B13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1073\/pnas.82.3.896","article-title":"The liver excretes large amounts of heme into bile when heme oxygenase is inhibited competitively by Sn-protoporphyrin.","volume":"82","author":"Kappas","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021121011035098500_B14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hep.1840040227","article-title":"Control of heme oxygenase and plasma levels of bilirubin by a synthetic heme analogue, tin-protoporphyrin.","volume":"4","author":"Kappas","year":"1984","journal-title":"Hepatology"},{"key":"2021121011035098500_B15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI112309","article-title":"and Drummond, GS. Control of heme metabolism with synthetic metalloporphyrins.","volume":"77","author":"Kappas, A","year":"1986","journal-title":"J Clin Invest"},{"key":"2021121011035098500_B16","first-page":"485","article-title":"The use of Sn-protoporphyrin in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility.","volume":"81","author":"Kappas","year":"1988","journal-title":"Pediatrics"},{"key":"2021121011035098500_B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.93.1.1","article-title":"Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin.","volume":"93","author":"Valaes","year":"1994","journal-title":"Pediatrics"},{"key":"2021121011035098500_B18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1542\/peds.95.4.468","article-title":"Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns.","volume":"95","author":"Kappas","year":"1995","journal-title":"Pediatrics"},{"key":"2021121011035098500_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.103.1.1","article-title":"Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-Mesoporphyrin.","volume":"103","author":"Martinez","year":"1999","journal-title":"Pediatrics"},{"key":"2021121011035098500_B20"},{"key":"2021121011035098500_B21"},{"key":"2021121011035098500_B22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1542\/peds.90.3.401","article-title":"Neonatal hyperbilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency in Sephardic Jewish infants: incidence, severity and the effect of phototherapy.","volume":"90","author":"Kaplan","year":"1992","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/1\/25\/893597\/25.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/1\/25\/893597\/25.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:33:39Z","timestamp":1682746419000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/108\/1\/25\/66924\/A-Single-Dose-of-Sn-Mesoporphyrin-Prevents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2001,7,1]]},"published-print":{"date-parts":[[2001,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.108.1.25","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,7,1]]}}}